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 25 
Abstract 26 
Background 27 
 28 
Enteral feeding will induce remission in as many as 80-90% of compliant patients with active Crohn’s 29 
Disease (CD) but its method of action remains uncertain.  This study was designed to examine its effects 30 
on the colonic microbiome.  31 
 32 
Method 33 
 34 
Healthy volunteers and patients with CD followed a regimen confined to enteral feeds alone for one or two 35 
weeks respectively. Chemicals excreted on breath or in faeces were characterised at the start and at the end 36 
of the feeding period by gas chromatography mass spectrometry (GC/MS). 37 
 38 
Results 39 
One week of feeding in healthy volunteers caused significant changes in stool colour and deterioration in 40 
breath odour, together with increased excretion of phenol and indoles on the breath.  Feeding for two weeks 41 
in patients with CD produced significant improvements in symptoms and a decrease in the concentration 42 
of C-reactive protein. The faecal concentrations of microbial products including short chain fatty acids 43 
(SCFAs), and potentially toxic substances including 1-propanol,  1-butanol and the methyl and ethyl esters 44 
of SCFAs showed significant falls.   45 
 46 
Conclusion 47 
 3 
 
A significant change occurs in the production of microbial metabolites after enteral feeding in both healthy 48 
volunteers and patients with CD.  Many of those detected in CD are toxic and may feasibly lead to the 49 
immunological attack on the gut microbiota, which is characteristic of IBD.  The reduction in the production 50 
of such metabolites after enteral feeding may be the reason for its effectiveness in CD. 51 
 52 
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 74 
 75 
Introduction 76 
Despite the increasing frequency of Crohn’s disease, its treatment remains unsatisfactory.  Many of the 77 
therapeutic agents used have unpleasant or even dangerous side effects and some are very expensive.  The 78 
continuing perception of CD as a relapsing and remitting disorder emphasises the difficulty in maintaining 79 
long term control.  A complete cure remains elusive.  80 
 81 
Reports of a positive response to dietary manipulation in CD have emerged from several sources.1-8   2-4 82 
weeks of total enteral feeding has been reported to reduce remission in 85-90% of compliant patients 83 
suffering active CD. 1-6.  Lack of understanding of the method of action of enteral feeds in CD has however, 84 
discouraged their use. 2-8   85 
 86 
Enteral feeds are nutritionally complete liquid mixtures of pre-digested foods presenting nitrogen as amino 87 
acids, oligopeptides or a single protein, carbohydrates as simple sugars, typically malto-dextrins, and fat as 88 
a single oil, (eg. Rapeseed oil), together with minerals and vitamins.  89 
Suggestions as to the method of action of enteral feeding are many, but it is now known that bowel rest  7 90 
and the reduction of potential food allergens 2-4   are incorrect.  Enteral feeding is unlikely to have 91 
therapeutic benefit by producing immunosuppression as it is ineffective in the treatment of ulcerative 92 
colitis. 3    Reduction in inflammation can be detected before any improvement in nutritional state begins, 8   93 
and the suggestion that dietary particles might be important was not supported by a controlled trial. 9   94 
 95 
The increasing evidence that inflammation in CD is provoked by an immune response targeted against the 96 
intestinal microbiome implies that manipulation of the metabolic activity of the microbiota might have a 97 
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role in the treatment of this disease 10,12 We and others have recently demonstrated an association between 98 
Crohn’s disease and the profile volatile organic compounds obtained from breath and faecal headspace 99 
samples 16,25. These measurements are a useful indication of changes in the gut microbiome, being simple, 100 
rapid and non-invasive. We have used this approach here in a study of the effects of enteral feeding.  It has 101 
been suggested that food intolerance, as distinct from food allergy, might reflect an interaction between 102 
unabsorbed food residues and the intestinal microbiome.13      As the nutrients contained in enteral feeds are 103 
absorbed high in the small intestine, they supply little in the way of energy substrates to micro-organisms 104 
in the lower bowel. This might lead to changes in microbial metabolism which in turn could lead to a 105 
reduction in inflammation.   The present studies were designed to investigate this possibility. 106 
 107 
Methods 108 
Study 1  Healthy volunteers 109 
Volunteers were recruited from students of either sex aged 18-65 years, at Cranfield University who were 110 
in good health and eating a normal diet. A total of 12 subjects was recruited aged 23-32, of which 8 were 111 
female. Subjects suffering conditions possibly requiring specific diets e.g. irritable bowel syndrome (IBS), 112 
or coeliac disease were excluded.  Other exclusions were pregnancy or lactation, a course of antibiotics in 113 
the previous six weeks, bacterial products such as pro- or pre- biotics and any chronic medication other 114 
than oral contraceptives. 115 
 116 
Subjects were randomly allocated to take either E028 extra (Nutricia UK Liverpool), or Modulen-IBD 117 
(Nestle Ltd, Croydon UK), for 7 days with all other foodstuffs excluded except water ad libitum..  118 
Nutritional requirements were calculated for each individual using Schofield’s equation. 14    119 
After 7 days subjects returned to normal diets for 21 days before commencing the alternative enteral feed 120 
for a further 7 days.  The two feeds were administered 4 weeks apart in order that they were taken at the 121 
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same stage of the menstrual cycles of female volunteers. During enteral feeding, subjects were asked to 122 
record how much feed they consumed and to complete symptom score sheets recording on a daily basis 123 
stool frequency, consistency and colour and any changes in breath odour.  Weights were recorded and 124 
breath samples taken before the study and after each week of enteral feeding.  This trial was an open, 125 
randomised controlled study performed at Cranfield University and approved by the ethics committee of 126 
Cranfield University and the NHS Cambridge local research ethics committee. 127 
Volunteers were provided with a sheet depicting a range of faecal colours ranging from dark brown to 128 
bright green (copies supplied to the editor) and asked to assess the stool colour, consistency and frequency.  129 
They were asked to record daily changes in breath odour which was assessed subjectively on a scale from 130 
1 (odourless) to 4 (extremely unpleasant). 131 
Bio-VOC samplers were used according to manufacturer’s recommendations to obtain a one-litre end-tidal 132 
breath sample after breakfast on the first day of each feeding period. Samples were injected onto Thermal 133 
desorption tubes containing 1:1 Tenax TA and Carbotrap adsorbents (Markes International, Llantrisant, 134 
UK). 135 
Study 2  Patients with Crohn’s disease 136 
Patients aged 18-65 years were recruited in the department of Gastroenterology, Addenbrooke’s Hospital, 137 
Cambridge. A total of 17 patients each provided a faecal sample before treatment with enteral feed 138 
E028extra  and again when they went into remission. At recruitment, all had symptoms of active disease.   139 
The diagnosis of CD was made by standard diagnostic criteria and the severity of symptoms was assessed 140 
using the Harvey and Bradshaw Index15.  The concentration of C-reactive protein (CRP) in serum samples 141 
obtained at each visit was determined by the Biochemistry Department of Addenbrooke’s Hospital to 142 
provide an objective measure of disease activity.   143 
 144 
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Any patients who had received antibiotics in the previous 6 weeks were excluded.  Some were taking 145 
medication including 5-aminosalicylic acid compounds and/or azathioprine which had been insufficient to 146 
control their symptoms, but none had received previous dietary treatment. They were asked to continue 147 
such medication during the period of feeding with elemental diet. Non-fasting morning samples of faeces 148 
were obtained before starting two weeks treatment with E028 extra (Nutricia Liverpool UK) with amounts 149 
again being calculated by Schofield’s equation.  A further faecal sample was obtained at the end of this 150 
period.  Samples were delivered to the hospital on the same day as passed with a maximum delay before 151 
freezing of 4 hours.  They were stored at -40°C until transferred to the laboratory for analysis. 152 
Ethical permission for this study was granted by the Leeds West LREC (Ref: 07/Q1205/39). 153 
Laboratory analysis   154 
An internal standard solution comprising 50 ng deuterated (D8) toluene (Supelco Cat no 48,593) in 155 
methanol was added to each tube according to the manufacturer’s instructions (Markes International Ltd, 156 
Llantrisant,UK). Head space samples were analysed by automated thermal desorption gas 157 
chromatography/mass spectrometry.  A Perkin Elmer system was used for analysis combining a TurboMass 158 
MS 4.1 Autosystem XL GC and Automatic Thermal Desorption system (ATD 400 PerkinElmer, Wellesley 159 
MA).  The gas carrier was CP-grade helium (BOC gases Guildford UK) passed through a combined trap 160 
for removal of hydrocarbons, oxygen and water vapour.  A wall-coated Zebron ZB624 chromatographic 161 
column was used with dimensions 60 x .04 x 0.25mm (internal diameter), the liquid phase comprising a 162 
0.25 µm layer of 6% cyanopropylphenyl and 94% methylpolysiloxane. 163 
 164 
Thermal desorption tubes were initially purged for 2 minutes to remove air and water vapour and then 165 
desorbed for 5 minutes at 300°C. The automatic thermal desorption valve temperature was set at 180°C 166 
and TD tubes were desorbed onto the secondary cold trap, which was initially maintained at 30°C.  Once 167 
desorption was complete, the secondary trap was heated to 320°C using the fastest available heating rate 168 
and then maintained for 5 minutes. The effluent was transferred to the gas chromatograph through a transfer 169 
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line heated to 210°C.  The gas chromatograph oven was maintained at 50°C for 4 minutes after injection 170 
and then raised at a rate of 10°C/min to 220°C and then held for 9 minutes.  Eluted products were transferred 171 
to the mass spectrometer via a line heated to 240°C. Electron ionisation (70eV) was used.  Full scan mode 172 
was selected with mass-to-charge ratios from 33 to 350 m/z with a scan time of 0.3 second and 0.1 second 173 
interscan delay to produce a total ion count (TIC) chromatogram. 174 
Study 2  175 
Samples were transferred to the laboratory packed in dry ice inside insulated containers and on arrival were 176 
stored at -80°C until analysis.   177 
Aliquots (5ml) of the defrosted samples were placed in gas sampling bags which were then sealed and filled 178 
with hydrocarbon-free air and incubated for 10 minutes at body temperature. A portable air pump was then 179 
used to draw 500ml of headspace through  TD tubes packed with 50% Carbotrap and 50% Tenax. Full 180 
details have been published elsewhere 16 181 
 182 
Data and statistical analysis 183 
 Study 1 184 
Compound identification was achieved using Automated Mass Spectral Deconvolution and Identification 185 
(AMDIS version 2.62) software and the National Institute of Standards and Technology mass spectral 186 
library.  Quantification was achieved by comparing the area of each compound peak with the peak area 187 
associated with the known amount of d8 toluene. 188 
 189 
Concentration data proved to be heavily right-skewed, therefore a non-parametric approach was adopted. 190 
A McNemar test was used to determine whether the probability of a compound to be present before or after 191 
the diet was significant.  When present a Wilcoxon Rank Test was used to see if the compound was present 192 
in different quantities. Raw TIC data (i.e. a matrix of time vs. ion abundance) were also subjected to 193 
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Principal Components Analysis (PCA)27 using Matlab (version 6/5 Mathworks Inc USA incorporating 194 
functions from the PLS Toolbox version 2.0 Eigenvector Research Inc USA). 195 
Study 2  196 
Compound identification and quantification were carried out as for study 1. In any given faecal headspace 197 
sample, automated mass spectral deconvolution and identification (AMDIS) would identify between 100-198 
300 different compounds and it was therefore found necessary to select a subset of those we observed to 199 
render statistical analysis tractable.  Three approaches were followed to provide a list of what we have 200 
termed ‘candidate compounds’.  The list comprised first compounds that appeared to be most abundant 201 
from inspection of the results obtained using AMDIS; second compounds that appeared to discriminate 202 
between patient groups by visual inspection of a subset of pre-treatment sample chromatograms and third 203 
compounds selected on the basis of a search of the relevant literature. An initial generic list was made 204 
including short-chain fatty acids (SCFAs) and their derivatives, phenolic compounds and indoles and 205 
sulfides.  This list was then refined according to publications dealing more explicitly with VOC profiles in 206 
disease.  A final list of compounds was obtained in this way. 207 
 208 
Results  209 
Study 1  210 
 211 
Of the 12 volunteers recruited, two females withdrew before the feeding commenced.  During the first 212 
feeding period 2 withdrew after 2 days feeding, one (female having E028) because of persistent hunger and 213 
the other (male having Modulen-IBD) because of insomnia attributed to an empty stomach.  Eight subjects 214 
completed the first phase.  A further subject (male Modulen-IBD) withdrew after 4 days in the second phase 215 
because of malaise and headaches.   216 
 217 
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Stool consistency and frequency showed no change.  There was a consistent change in stool colour from 218 
browns towards green on E028 extra (r=0.639, p<0.05 Spearman test), and a similar but less marked effect 219 
was seen after Modulen-IBD (r=0.598, p<0.05).  Faecal colour had returned to normal by the start of the 220 
second feeding period. 221 
 222 
All subjects showed deterioration in odour on E028 extra and 5 out of 6 on Modulen-IBD.  One volunteer 223 
did not record his breath changes on a daily basis. A Spearman test showed a significant difference between 224 
the odour of the breaths of the volunteers before they started and the last day of the diet (E028 extra r=0.575 225 
p<0.05, Modulen-IBD r=0.574 p<0.05). Subjects’ breath odour had returned to normal at the start of the 226 
second feeding period. Numerical results were presented as mean with upper and lower quartiles. The 227 
frequency distributions for all compounds were found to be highly skewed with a proportion of nondetects; 228 
therefore, a nonparametric statistical approach was adopted. 229 
 230 
Over 140 compounds were seen in the breath analysis including aldehydes, ketones, saturated and non-231 
saturated hydrocarbons, organic acids, alkenes, alcohols and furans.  The compounds also varied between 232 
volunteers. As at least one third of compounds were known to be environmental contaminants, e.g. benzene, 233 
toluene, xylene, we concentrated on two marker compounds known to be bacterial metabolites, phenol and 234 
indole. 235 
 236 
The mean alveolar gradient for indole on a normal diet was 0.034 ±  SD 0.029.  There was little change 237 
following  Modulen-IBD  0.041 ±  SD 0.028 (NS).  After E028 it rose to 0.149 ±  SD 0.099 (NS)  The 238 
differences between the values after diet did not differ significantly from those before, but the aveolar 239 
gradient after E028 was significantly higher than that after Modulen-IBD (P<0.03). 240 
 241 
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The mean level of alveolar gradient for phenol on the breath on a normal diet was 0.024 ± SD 0.017.  After 242 
Modulen-IBD it rose to 0.055 ±  SD 0.025 (NS).  After E028 the levels were 0.229 ±  SD 0.152 (p<0.05).  243 
The increase after E028 was significantly greater to that after Modulen-IBD P=0.035  After 3 weeks of 244 
normal eating, breath chemicals had in every case returned to levels indistinguishable from those present 245 
at the start of the first period of enteral feeding. 246 
 247 
Results 248 
Study 2:  249 
 250 
At the start of treatment all 17 patients had active disease as confirmed by a Harvey and Bradshaw index 251 
of >6 and raised concentration of C-reactive protein (CRP) in the blood. 9 patients were receiving no 252 
medication, 4 were taking 5ASA compounds, 2 were taking 5ASA with Azathioprine, 1 taking 253 
Azathioprine alone and 1 taking Azathioprine and Prednisolone. Patients were asked to continue the same 254 
medication throughout the study and this was not changed in any way, remission being achieved in all cases 255 
by the addition of enteral feed.  The mean Harvey & Bradshaw (H&B) before treatment was 6.88 ±  SD 256 
2.93 falling to 4 ± SD 5.50 after treatment, (p<0.05).  The initial mean CRP was 36.0 ±  SD 41.3mg/L 257 
falling to 8.11 ±  SD 3.59 after treatment (p<0.05).  258 
 259 
The results of GC/MS faecal analysis are summarised in Table 1. Many compounds of known bacterial 260 
origin were present in the initial sample.  These included propanoic and butanoic acids, para-cresol, indole, 261 
dimethyl disulphide and phenol.  The concentrations of the SCFAs fell dramatically after enteral feeding.  262 
No difference was discerned in the fall of concentrations of bacterial metabolites in those subjects receiving 263 
enteral feeds alone, and those who continued their previous medication. Thus the results of all the patients 264 
were analysed together.  265 
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 266 
There were also however, a number of potentially toxic compounds present.  These included the alcohols, 267 
1-propanol and 1-butanol as well as the methyl and ethyl esters of propanoic acid and butanoic acid.  After 268 
treatment, the amounts of these compounds also fell significantly.   The SCFA-esters disappeared virtually 269 
completely and there was a significant fall in the concentration of 1-propanol and 1-butanol.  However, 270 
other chemicals including those derived by bacterial breakdown of amino acids, phenol and indole did not 271 
change significantly (table 1).   272 
 273 
Discussion 274 
 275 
The present study demonstrates changes in chemicals of microbial origin in both healthy controls and in 276 
patients with CD after administration of enteral feeds.  Our first study confirms reports of stool colour  277 
change during treatment with the development of breath odour. It is probable that this was the result of the 278 
cessation of the normal microbial breakdown of biliverdin (green) to stercobilin (brown).  279 
 280 
We also attempted to assess bacterial activity by determination on the breath of known bacterial metabolites 281 
that might be absorbed into the blood stream from the colon.  Many chemicals are present in breath and 282 
urine and we detected 140. Their origins of many are poorly understood.  We therefore concentrated on 283 
changes in the excretion of two chemicals whose synthesis by the microbiota is well understood, namely 284 
phenol and indole.14,15 285 
 286 
Phenol and indole are produced by the microbial conversion of tyrosine and tryptophan respectively.  Much 287 
less is produced when carbohydrate fermentation is continuing in the colon.  Conversely, when 288 
carbohydrate was withdrawn from the diet, phenol production from endogenous protein sources such as 289 
intestinal secretions and exfoliated cells was increased 17,18   290 
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 291 
 In the present study, phenol and indole identified on the breath showed a significant increase in 292 
concentration after feeding with Modulen-IBD and an even greater increase after E028extra, which rapidly 293 
returned to base line on resumption of a normal diet.    This is consistent with a switch in colonic 294 
fermentation to a protein-based pattern, as an effect of ingesting carbohydrate in the form of maltodextrins 295 
- simple sugars that are absorbed high in the small intestine - rather than complex carbohydrates that may 296 
pass down to be fermented by the colonic flora. Indole is malodorous and may contribute to the unpleasant 297 
breath odour reported by our volunteers.    298 
 299 
The effect of E028 on phenol and indole was greater than that of Modulen IBD.  The may be related to the 300 
content of  long chain triglyceride in the feeds which we and others have shown to be an important factor 301 
influencing their effectiveness. 2,28   The LCT content of Modulen IBD is greater than that of E028 extra.  302 
 303 
The term ‘enterometabolic disease’ has been suggested for non-infective conditions arising from abnormal 304 
fermentation by the colonic microbiota 13. Patients with IBS have a similar abnormal gut flora to that seen 305 
in CD.11,20,23 and have a markedly increased excretion of a bacterial product, hydrogen. This was 306 
dramatically reduced, with highly significant reduction in symptoms, when patients were switched from a 307 
standard diet to an exclusion diet, suggesting that the diet reduced microbial activity 24.  Support for this 308 
concept was provided by the demonstration of reduced hydrogen excretion in patients with IBS , again with 309 
significant improvement in symptoms, when microbial activity was reduced  by administration of 310 
antibiotics or by enteral feeding .25 311 
Is  it possible that CD like IBS may be an ‘entero-metabolic disorder’, 13  and that enteral feeding  is effective 312 
because it reduces the metabolic activity of an abnormal colonic flora? 313 
 314 
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There is strong evidence that the host microflora provokes an immunological response in CD.  Duchmann 315 
and his colleagues showed that monocytes from the peripheral blood and the lamina propria were activated 316 
when incubated with preparations of faecal bacteria from other subjects, but not by such preparations 317 
derived from the faeces of the host.  Monocyte activation occurred only when host faeces was incubated 318 
with cells obtained from the lamina propria from sites of active CD. No activation was seen in monocytes 319 
obtained from areas where no active CD was present, suggesting that monocytes in areas of active CD were 320 
specifically targeted against the host microflora.10 321 
 322 
This finding has been supported by later studies that demonstrated that the great majority of microrganisms 323 
found in the faeces of patients with IBD were coated with immunoglobulin, including IgA, IgG and IgM, 324 
whereas in normal subjects or those with IBS, less than 20% were so affected 12.   325 
Furthermore, a significant reduction in the number of microorganisms coated with immunoglobulin was 326 
seen after 2 weeks treatment with corticosteroids in UC, and a similar response occurred in CD after a two 327 
week course of elemental feeding.  This suggested that the immune response to the flora had been 328 
significantly reduced, an interpretation supported by the finding that patients with CD and UC in long term 329 
remission had similar numbers of coated bacteria to those seen in healthy controls.12    330 
No specific pathogen has as yet been confirmed as being the cause of CD, but it has been demonstrated that 331 
the faecal flora is abnormal with an overgrowth of facultative anaerobes and reduction in the numbers of 332 
important beneficial species such as Lactobacilli and Bifidobacter.11,20    Although previous studies of the 333 
effects of enteral feeding on the composition of the bacterial flora in CD, had been inconclusive,21,22    334 
a recent study of the entire gut mucosal microbiome in a child with CD before and after nutritional therapy 335 
showed that the flora, initially markedly abnormal, returned after therapy, to a pattern very similar to that 336 
found in a healthy control 26.  Likewise, it has also been shown that enteral nutrition in CD may reduce the 337 
levels of certain bacteria within the Firmicutes.  These bacteria are important producers of SCFAs and this 338 
report is in keeping with our discovery of reduced SCFA production. 27   339 
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 340 
Unfortunately, it was not possible in the present study to perform complex studies of changes in the gut 341 
microbiome, but changes in bacterial metabolites serve as valuable markers of its metabolic activity. SCFAs 342 
have an important function in the colon especially butanoic acid which is a major source of nutrition for 343 
colonocytes.19  They are produced by the microbial fermentation of undigested complex carbohydrates 344 
entering the caecum and the fall in faecal SCFA concentration found after enteral feeding in our patients 345 
with CD was consistent with reduction in colonic fermentation.   346 
 347 
Such a reduction in fermentation might be beneficial if it resulted in less production of toxic metabolites.  348 
There were highly significant falls in the concentrations of number of chemicals including 1-propanol, p-349 
cresol, phenol, 1-butanol, dimethyl disulphide and fatty acid ethyl esters  (Table 1).  These are known to be 350 
toxic chemicals which we have shown not to be present in the stools of healthy volunteers. 16   It seems 351 
possible that the production of such chemicals might be a factor initiating an immune attack on the 352 
microflora.   This could lead to coating of microflora with immunoglobulin – a suggestion which has been 353 
supported by the significant reduction in bacterial coating seen after 2 weeks feeding with enteral feeds.12,16 354 
 355 
Similar toxic chemicals also appear in UC, but in contrast to CD, do not fall after enteral feeding, but only 356 
after successful treatment by immunosuppression with prednisolone16. Although evidence on the role of 357 
diet in UC remains weak, this suggests that the microflora in UC differs from that in CD in that it derives 358 
its nutritional requirements, not from food residues, but from other substances present in the large intestine 359 
– possibly mucus or intestinal secretions.   It is therefore feasible, that the production of toxic chemicals 360 
resulting from abnormal bacterial metabolism, may be an important factor in the initiation of an immune 361 
attack on the microflora in inflammatory bowel disease. 362 
 363 
 364 
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Table 1 Changes in faecal chemicals before and after elemental feeding in patients with Crohn’s 365 
disease 366 
 367 
 VOC concentration (ng/l) 
Median (lower quartile, upper 
quartile) 
Compound Pre-
treatment 
Post-
treatment 
p-value 
acetone 
57 
(38, 128) 
80 
(50, 104) 
0.435 
propanoic acid 
169 
(0, 328) 
12 
(0, 84) 
0.031* 
butanoic acid 
1110 
(316, 1596)) 
24 
(0, 104) 
0.001* 
1-propanol 
229 
(41, 892) 
36 
(0, 233) 
0.025* 
propanoic acid, ethyl ester 
19 
(0, 117) 
0 
(0, 15) 
0.008* 
butanoic acid, methyl ester 
19 
(7, 121) 
0 
(0, 1) 
0.013* 
butanoic acid, ethyl ester 
46 
(4, 255) 
0 
(0, 15) 
0.008* 
p-cresol 
518 
(118, 1160) 
480 
(144, 1051) 
0.687 
indole 
118 
(54, 146) 
20 
(0, 128) 
0.125 
dimethyl disulphide 
83 
(34, 683) 
39 
(0, 140) 
0.113 
1-butanol 
99 
(57, 256) 
58 
(0, 199) 
0.030* 
butanoic acid, 3-methyl 
147 
(48, 504) 
0 
(0, 45) 
0.015* 
phenol 
64 
(16, 102) 
24 
(10, 177) 
0.332 
 368 
 369 
 370 
 371 
 372 
 17 
 
Reference List 373 
 374 
1. O’Morain C, Segal AW, Levi AJ, Elemental diet as primary treatment of acute Crohn’sdisease: 375 
A controlled trial BMJ 1984 288: 1859-62 376 
2. Middleton SJ, Rucker JT, Kirby GA, Riordan AM, Hunter JO Long chain triglycerides reduce 377 
the efficacy of enteral feeds in patients with active Crohn’sdisease.  Clinical Nutrition 1995 14 378 
229-236  379 
 380 
3. King TS, Woolner JT, Hunter JO Dietary treatment of Crohn’sdisease Review article – The 381 
Dietary management of Crohn’sdisease Aliment. Pharm. Toxicol 11 17-31 1997 382 
 383 
4. Walker-Smith J (2001) The role of enteral feeding in Crohn’sdisease of childhood Minerva 384 
Pediatr. 52 277-9 385 
 386 
5. Gupta K, Noble A, Kachelries KE, Albenberg L, Kelsen JR, Grossman AB, Baldassano RN  A 387 
novel enteral nutrition protocol for the treatment of pediatric Crohn’sdisease.  Inflammatory 388 
Bowel Diseases 2013 19 1374-8 389 
 390 
6. Brown AC, Roy M, Does evidence exist to include dietary therapy in the treatment of 391 
Crohn’sdisease? Expert Review of Gastroenterology and Hepatology 2010 4 191-215 392 
 393 
7. Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine     Controlled 394 
trial of bowel rest and nutritional support in the management of Crohn’s  disease.WJ. Gut. 1988 395 
Oct; (10):1309-15 396 
 397 
 18 
 
8. Teahon K, Pearson M, Smith T, Bjarnason I, Alterations in nutritional status and disease activity 398 
during treatment of Crohn’sdisease with elemental diet Scan J Gastroenterol.1995  30 54-60  399 
 400 
9. Lomer MC, Grainger SL, Ede R et al Lack of efficacy of a reduced microparticle diet in a 401 
multicentered trial of patients with active Crohn’sdisease.  Euro J Gastroenterol Hepatol 2005 402 
17 377-84 403 
 404 
10. Duchmann R, Kaiser I, Hermann E, Mayet W, Meyer zum Buschenfelde KE and KH Tolerance 405 
exists towards intestinal flora but is broken in active Inflammatory Bowel Disease Clin. Exp. 406 
Immunol. 1995 102 448-455 407 
 408 
11. Albenberg LG, Lewis JD, Wu GD, Food and the Gut microbiota in inflammatory bowel disease; 409 
a critical connection. Current Opinion in Gastroenterology 2012 28 314-20 410 
 411 
12. Van der Waaij LA, Kroese FG, Visser A, Nelis GF, Westenveld BD, Jansen PL, Hunter JO 412 
Immunogloblulin of faecal bacterial in Inflammatory Bowel Disease Eur. J Gastroenterol 413 
Hepatol. 2004 16 669-74 414 
 415 
13. Hunter JO Food Allergy – or entero metabolic disorder Lancet 1991 338 495-6 416 
 417 
14. Schofield WN Predicting Basal metabolic rate, new standards and review of previous work. 418 
Hum Nutr Clin Nutr 1985 39C: 5-41   419 
 420 
15. Harvey RF, Bradshaw JM, A simple index of Crohn’sdisease activity Lancet 1980 i 514 421 
 422 
 19 
 
16. Walton C, Fowler DP, Turner C, Jia W, Whitehead RN, Griffiths L, Dawson C, Waring RH, 423 
Ramsden DB, Cole JA, Cauchi M, Bessant C, Hunter JO. Analysis of volatile organic 424 
compounds of bacterial origin in chronic gastrointestinal diseases.  Inflamm Bowel Dis. 2013 19 425 
2069-78 426 
 427 
17. Cummings JH, Hill MJ, Bone ES, Branch WJ, Jenkins DJA The effect of meat protein and 428 
dietary fiber on colonic function and metabolism II Bacterial metabolites in faeces and urine.  429 
Am J Clin Nutr 1979 32 2094-2101 430 
 431 
18. Macfarlane GT, Cummings JH, Allison C Protein degradation by human intestinal bacteria J 432 
Gen Microbiol 1986 132 1647-56 433 
 434 
19. Roediger WE, Oxidative and synthetic functions of n-Butyrate in colonocytes Dis Colon 435 
Rectum 1992 35 511-12     436 
 437 
20. Sartor RB, Theraputic manipulation of the enteric microflora in inflammatory bowel diseases; 438 
antibiotics, probiotics and probiotics.  Gastroenterology 2004 126 1620-33    439 
 440 
21. Kaakoush NO, Day AS, Leach ST, Lemberg DA, Nielsen S Mitchell HM. Effect of exclusive 441 
enteral nutrition on children with newly diagnosed Crohn’s disease. Clin Trans Gastroenterol. 442 
2015; 6, e71; doi: 10.1038/ctg.2014.21 443 
22. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker B. The role of short-444 
chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. 2013 445 
J. Lipid Res. 54: 2325-2340. 446 
23. Garner CE, Smith S, Costello BD, White P, Spencer R, Probert CSJ, Ratcliffe NM. Volatile 447 
organic compounds from feces and their potential for diagnosis of gastrointestinal disease. 2007 448 
Faseb J. 21(8): 1675-1688. 449 
24. Rehman A, Lepage P, Nolte A, Helmig S, Schreiber S, Ott SJ. Transcriptional activity of the 450 
dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. 2010 J. Med. 451 
 20 
 
Microbiol. 59(9): 1114-1122. 452 
25. Bodelier AGL, Smolinska A, BAranska A, Dallinga JW,Mujagic Z, Vanhees K, van der Heuvel 453 
T, Masclee AAM, Jonkers D, Pierik MJ, van Schooten FJ. Volatile Organic Compounds in 454 
Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach 455 
2015 Inflamm. Bowel Dis. 21(8): 1776-1785. 456 
26.  D’Argenio V, Precone V, Casaburi G, Miele E, Martinelli M , Staiano A, et al An altered gut 457 
microbiome profile in a child affected by Crohn’s  disease normalized after nutritional therapy.  458 
AmJ Gastroenterol 2013 108 851-852 459 
27. Shiga H, Jajiura T, Shinozaki J, Suzuki M, Takagi S, Kinouchi Y, Takahashi S, Shimosegawa T, 460 
Changes of faecal microbiota in Crohn’s disease treated with an elemental diet and total 461 
parenteral nutrition.  Digestive Liver disease 2012 44 736-42. 462 
28. Bamba, Tadao, Shimoyama et al.  Dietary fat attenuates the benefits of an elemental diet in 463 
active Crohn’s disease: a randomized controlled trial.  Eur J Gastro Hepatol 2003; 15(2):151-7  464 
 465 
 466 
Acknowledgements: 467 
 468 
This work was supported by the Wellcome Trust (Grant no. 080238/Z/06/Z).   469 
Conflicts of interest: Professor J O Hunter has received grants for research and honoraria for speaking from 470 
both Nutricia UK and Nestle UK. 471 
  472 
 21 
 
SUPPORTING INFORMATION 473 
Declaration of funding interests: 474 
The work for this study was funded by the Wellcome Trust Grant No. 080238/Z/06/Z.  Professor Hunter 475 
has acted as a consultant and received research grants from Nutricia (UK) Liverpool and from Nestle. 476 
 477 
STROBE STATEMENT 478 
All items on the strobe checklist have been checked and confirmed to be included in this paper. 479 
